U.S. markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.09 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.88 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    +0.25 (+0.31%)
     
  • Gold

    1,668.30
    -3.70 (-0.22%)
     
  • Silver

    19.01
    -0.02 (-0.13%)
     
  • EUR/USD

    0.9802
    -0.0017 (-0.18%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • GBP/USD

    1.1120
    -0.0003 (-0.03%)
     
  • USD/JPY

    144.6340
    +0.1910 (+0.13%)
     
  • BTC-USD

    19,248.14
    +1.66 (+0.01%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.89 (-1.84%)
     

Cassava Insiders Got A Lot Richer As Shares Rebound Following Refutation of Data Manipulation Claims

·1 min read
  • Journal of Prevention of Alzheimer's Disease (JPAD) informed Cassava Sciences Inc (NASDAQ: SAVA) about no convincing evidence to support data manipulation allegations in a 2020 paper on simufilam co-authored by the company's personnel and its science collaborators.

  • Simufilam, Cassava's Alzheimer's candidate, is a small molecule (oral) drug that restores the normal shape and function of altered filamin A protein in the brain.

  • "From the onset, I have said that allegations of research misconduct are false, and for a good reason – I see no supporting evidence for the allegations," said Remi Barbier, President & CEO.

  • "I'm hopeful that written pronouncements from neutral and independent science experts will help close the chapter of baseless attacks against our science."

  • Related Content: Cassava Sciences Shares Plunge After Criminal Investigation Report.

  • In May 2022, Neurobiology of Aging investigated and found no evidence of data manipulation in a paper on simufilam published in that journal in 2017.

  • In December 2021, Cassava Sciences announced that Neuroscience investigated and found no evidence of data manipulation in a paper published in 2005.

  • In November 2021, Cassava Sciences announced that The Journal of Neuroscience investigated and found no evidence of data manipulation in a paper on simufilam published in July 2012.

  • Price Action: SAVA shares are up 1.79% at $26.18 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.